Beam Therapeutics/$BEAM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
- Ticker
- $BEAM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 557
- Headquarters
- Cambridge, United States
- Website
- beamtx.com
BEAM Metrics
BasicAdvanced
$2.6B
-
-$1.04
2.22
-
Price and volume
Market cap
$2.6B
Beta
2.22
52-week high
$38.26
52-week low
$20.23
Average daily volume
1.8M
Financial strength
Current ratio
13.005
Quick ratio
12.718
Long term debt to equity
0.24
Total debt to equity
0.256
Interest coverage (TTM)
-61.38%
Profitability
EBITDA (TTM)
-370.407
Gross margin (TTM)
-178.91%
Net profit margin (TTM)
-73.89%
Operating margin (TTM)
-267.68%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-19.02%
Return on equity (TTM)
-11.29%
Valuation
Price to revenue (TTM)
18.313
Price to book
2.71
Price to tangible book (TTM)
2.71
Price to free cash flow (TTM)
-6.743
Free cash flow yield (TTM)
-14.83%
Free cash flow per share (TTM)
-3.836
Growth
Revenue change (TTM)
163.27%
Earnings per share change (TTM)
-76.29%
3-year revenue growth (CAGR)
21.60%
3-year earnings per share growth (CAGR)
-37.15%
What the Analysts think about BEAM
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
Analyst projections of the future price of Beam Therapeutics stock.
Bulls say / Bears say
BEAM-301’s first six-patient readout offers early proof of concept: two of three patients at 40 mg fasted for the full 15 hours and no longer needed starch supplements. The result is preliminary, but it shows a potential meaningful benefit from a single treatment. (Beam Therapeutics)
BEAM-302 has produced durable rises in functional AAT above the protective threshold and an 84% reduction in mutant Z-AAT at 60 mg. Beam has started a roughly 50-patient pivotal cohort and plans to seek accelerated approval using 12-month biomarker data. (GlobeNewswire)
Risto-cel is approaching a key regulatory milestone in sickle cell disease: dosing is complete in the adult and adolescent BEACON trial, and Beam expects to submit its US application as early as year-end 2026. A successful filing would give the company a near-term route towards its first product launch. (Beam Therapeutics)
BEAM-301’s encouraging results come from only six patients, and treatment-related serious adverse events occurred in four, including three Grade 3 infusion reactions. The small, early study leaves both the safety profile and the apparent benefit uncertain. (Beam Therapeutics)
BEAM-302’s pivotal approval plan relies on AAT biomarkers rather than demonstrated improvement in how patients feel or function, with a confirmatory trial still to come. Its safety data are also not clean: 41% of patients had infusion reactions, and one patient with liver disease had a transient Grade 3 liver-enzyme rise. (GlobeNewswire)
Beam remains loss-making, with a $122.7 million net loss in the second quarter and management expecting operating losses and negative cash flow for the foreseeable future. It says its $1.2 billion cash balance should fund plans into mid-2029, but further financing may be needed and could dilute shareholders or add debt. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
BEAM Financial Performance
Revenues and expenses
BEAM Earnings Performance
Company profitability
Upcoming events
No upcoming events
BEAM News
AllArticlesVideos
Funds containing BEAM
AllUSDEURGBP
Fund name | Fund size | $BEAM weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 3.80% |
ARK Genomic Revolution£ARCG | $123M | 3.80% |
ARK Innovation£ARCK | $325M | 3.48% |
ARK Innovation€ARXK | $325M | 3.48% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.